Antibiogram and molecular profiling of non-respiratory isolates of Pseudomonas aeruginosa using ERIC-PCR in a tertiary care hospital
Abstract
Background and Objectives: Pseudomonas aeruginosa is a major nosocomial pathogen implicated in a wide range of hospital-acquired infections. Prompt detection and effective control of outbreaks caused by this organism are essential to minimize associated morbidity and mortality. Multiple strains may circulate within healthcare settings due to cross-transmission and persistent environmental reservoirs. Various molecular typing techniques have proven valuable in tracing the sources and transmission dynamics of outbreaks. The present study aimed to investigate the antibiogram profiles and enterobacterial repetitive intergenic consensus–polymerase chain reaction (ERIC-PCR) patterns of P. aeruginosa isolates recovered from non-respiratory clinical samples at a tertiary care hospital.
Materials and Methods: A total of 157 clinical isolates phenotypically identified as P. aeruginosa were subjected to 16S rDNA-PCR for species confirmation. Among these, 150 isolates were confirmed as P. aeruginosa and subsequently analysed for antimicrobial susceptibility and molecular typing. Antimicrobial susceptibility testing was performed according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Molecular typing was carried out using ERIC-PCR. The resulting ERIC-PCR profiles were analysed using PAST version 4.03 software, and a dendrogram was constructed based on Dice similarity coefficients to assess genetic relatedness among isolates. Fisher’s exact test was employed to determine associations between specific ERIC types and antibiotic resistance profiles.
Results: Overall, 84% of the P. aeruginosa isolates were identified as multidrug-resistant (MDR), with widespread distribution among both inpatients and outpatients. The highest resistance rate was observed against ticarcillin/clavulanic acid, followed by ceftazidime, whereas no resistance was detected against colistin sulphate. A total of 54 distinct antibiotypes were identified, indicating substantial variability in antimicrobial resistance patterns. All 150 isolates were successfully typed using ERIC-PCR, which revealed 41 distinct clusters at an approximate similarity coefficient of 70%, demonstrating considerable genetic diversity among the isolates.
Conclusion: This study enhances the understanding of the epidemiology of P. aeruginosa infections in healthcare settings by characterizing both the molecular diversity and antimicrobial resistance patterns of clinical isolates. The high prevalence of MDR strains and the circulation of multiple genetically diverse strains among hospital patients highlight the ongoing risk of transmission within the healthcare environment. Notably, the findings suggest a comparatively higher rate of cross-infection among burn patients. These observations underscore the urgent need for stringent infection prevention and control measures, particularly in burn units, to limit the spread of MDR P. aeruginosa.
2. Kerr KG, Snelling AM. Pseudomonas aeruginosa: a formidable and ever-present adversary. J Hosp Infect 2009; 73: 338–344.
3. Crone S, Vives‐Flórez M, Kvich L, Saunders AM, Malone M, Nicolaisen MH, et al. The environmental occurrence of Pseudomonas aeruginosa. APMIS 2020; 128: 220-231.
4. Hematzadeh A, Haghkhah M. Biotyping of isolates of Pseudomonas aeruginosa isolated from human infections by RAPD and ERIC-PCR. Heliyon 2021; 7(9): e07967.
5. Quick J, Cumley N, Wearn CM, Niebel M, Constantinidou C, Thomas CM, et al. Seeking the source of Pseudomonas aeruginosa infections in a recently opened hospital: an observational study using whole-genome sequencing. BMJ Open 2014; 4(11): e006278.
6. Mansouri S, Savari M, Malakian A, Abbasi Montazeri E. High prevalence of multidrug-resistant Enterobacterales carrying extended-spectrum beta-lactamase and AmpC genes isolated from neonatal sepsis in Ahvaz, Iran. BMC Microbiol 2024; 24: 136.
7. CLSI (2022). Performance standards for antimicrobial susceptibility testing. 32nd ed. CLSI supplement M100. Clinical and Laboratory Standards Institute. Wayne, PA.
8. Nitz F, de Melo BO, da Silva LCN, de Souza Monteiro A, Marques SG, Monteiro-Neto V, et al. Molecular detection of drug-resistance genes of blaOXA-23-blaOXA-51 and mcr-1 in clinical isolates of Pseudomonas aeruginosa. Microorganisms 2021; 9: 786.
9. Inacio HS, Bomfim MR, França RO, Farias LM, Carvalho MA, Serufo JC, et al. Phenotypic and genotypic diversity of multidrug-resistant Pseudomonas aeruginosa isolates from bloodstream infections recovered in the Hospitals of Belo Horizonte, Brazil. Chemotherapy 2014; 60: 54-62.
10. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-281.
11. Vitkauskienė A, Skrodenienė E, Dambrauskienė A, Macas A, Sakalauskas R. Pseudomonas aeruginosa bacteremia: resistance to antibiotics, risk factors, and patient mortality. Medicina (Kaunas) 2010; 46: 490-495.
12. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997; 25: 1094-1098.
13. Khosravi AD, Hoveizavi H, Mohammadian A, Farahani A, Jenabi A. Genotyping of multidrug-resistant strains of P. aeruginosa isolated from burn and wound infections by ERIC-PCR. Acta Cir Bras 2016; 31: 206-211.
14. Zakhour J, Sharara SL, Hindy JR, Haddad SF, Kanj SS. Antimicrobial treatment of Pseudomonas aeruginosa severe sepsis. Antibiotics (Basel) 2022; 11: 1432.
15. Ranjbar R, Owlia P, Saderi H, Mansouri S, Jonaidi-Jafari N, Izadi M, et al. Characterization of Pseudomonas aeruginosa strains isolated from burned patients hospitalized in a major burn center in Tehran, Iran. Acta Med Iran 2011; 49: 675-679.
16. Eladawy M, El-Mowafy M, El-Sokkary MMA, Barwa R. Antimicrobial resistance and virulence characteristics in ERIC-PCR typed biofilm-forming isolates of P. aeruginosa. Microb Pathog 2021; 158: 105042.
17. Mansour SA, Eldaly O, Jiman Fatani A, Mohamed ML, Ibrahim EM. Epidemiological characterization of P. aeruginosa isolates of intensive care units in Egypt and Saudi Arabia. East Mediterr Health J 2013; 19: 71-80.
18. Horcajada JP, Montero M, Oliver A, Sorlí L, Luque S, Gómez-Zorrilla S, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev 2019; 32(4): e00031-19.
19. Abdelaziz MA, El-Aziz AMA, El-Sokkary MMA, Barwa R. Characterization and genetic analysis of extensively drug-resistant hospital-acquired Pseudomonas aeruginosa isolates. BMC Microbiol 2024; 24: 225.
20. Sener B, Köseoğlu O, Ozçelik U, Kocagöz T, Günalp A. Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis. Int J Med Microbiol 2001; 291: 387-393.
21. Pelegrin AC, Palmieri M, Mirande C, Oliver A, Moons P, Goossens H, et al. Pseudomonas aeruginosa: a clinical and genomics update. FEMS Microbiol Rev 2021; 45(6): fuab026.
22. Abdel-Rhman SH, Rizk DE. Comparative assessment of different PCR-based typing methods of Pseudomonas aeruginosa isolates. Infect Drug Resist 2021; 14: 1019-1035.
| Files | ||
| Issue | Vol 18 No 4 (2026) | |
| Section | Original Article(s) | |
| Keywords | ||
| Pseudomonas aeruginosa Polymerase chain reaction (PCR) Multi drug resistance Molecular typing (ERIC) 16S Ribosomal gene (16S rRNA gene) Antibiogram Microbial sensitivity testing | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |



